Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy

Cancer

Volumn 95, Issue 4, 2002, Pages 888-895

  Crawford, Jeffrey ^a   Cella, David ^b   Cleeland, Charles S ^c   Cremieux, Pierre Yves ^d,e   Demetri, George D ^f   Sarokhan, Brenda J ^g   Slavin, Mitchell B ^g   Glaspy, John A ^h,i  

^a DUKE CANCER INSTITUTE   (United States)

^b Research and Education   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d Analysis Group/Economics   (United States)

^e UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g Ortho McNeil Pharmaceutical Incorporated   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NONE   (United States)

Author keywords

Anemia; Epoetin alfa; Erythropoietin; Hemoglobin; Neoplasm; Quality of life

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT;

ANEMIA; ANTINEOPLASTIC AGENTS; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 0037102975     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10763     Document Type: Article

References (43)

1. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer
2. Gemcitabine plus best supportive care (BSC) vs BSC in operable nonsmall cell lung cancer - A randomized trial with quality of life as the primary outcome
3. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A Phase III study of the European Organization for Research and Treatment of cancer
4. Efficacy of pamidronate in breast cancer with bone metastases: A randomized, double-blind placebo-controlled multicenter study
5. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. The Fatigue Coalition
6. Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition
7. Progress toward guidelines for the management of fatigue
8. Symptom prevalence, characteristics and distress in a cancer population
9. Chemotherapy-induced anemia in adults: Incidence and treatment
10. Decreased erythropoietin response in patients with the anemia of cancer
11. The quality of life of dialysis patients treated with recombinant human erythropoietin
12. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients
13. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis
14. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients
15. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin
16. Improvement of brain function in haemodialysis patients treated with erythropoietin
17. Low dose erythropoietin in maintenance haemodialysis: Improvement in quality of life and reduction in true cost of haemodialysis
18. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients
19. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin
20. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin
21. Working capacity is increased following recombinant human erythropoietin treatment
22. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin
23. Brain function is better in hemodialysis patients when hematocrit is normalized with erythropoietin [abstract]
24. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
25. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients
26. Erythropoietin for anaemia in cancer patients
27. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy
28. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
29. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
30. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
31. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin
32. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
33. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO)
34. Clinical benefits of epoetin alfa therapy in patients with lung cancer
35. The future of r-HuEPO
36. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue
37. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system
38. Sample selection bias as a specification error
39. The application of sample selection models to outcomes research: The case of evaluating the effects of antidepressant therapy on resource utilization
40. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function
41. On the choice between sample selection and two-part models